Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc. has demonstrated a promising financial trajectory with an estimated market value of $3.42 billion, indicating strong investor confidence and potential for growth. The company's recent equity financing has increased the projected shares outstanding to 34.9 million, which reflects a strategic move to enhance funding for its innovative therapeutics targeting serious eye and metabolic diseases. Furthermore, the interim analysis of the DRAGON trial suggests that sufficient efficacy and favorable safety data may be available, positioning Belite Bio favorably for potential FDA approval of its lead product, tinlarebant, which could significantly impact its market position and financial performance.

Bears say

Belite Bio Inc faces significant risks that could adversely affect its financial performance, particularly regarding the development of its lead candidate, tinlarebant. The company could encounter challenges such as failure in clinical trials, inability to secure regulatory approval in the U.S., and obstacles in achieving commercial success due to market dynamics and competition. Additionally, the potential for dilution poses further risks to existing shareholders, highlighting the uncertainty surrounding the company's future financial stability.

BLTE has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 3 analysts, BLTE has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $113.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $113.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.